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ABSTRACT 
The N-terminal segment (residues 1-15) of hexokinase I (HKI) is essential for the 
binding of HKI to the outer membrane of the mitochondrion.  Whether the N-terminal 
segment is merely a hydrophobic anchor to the membrane or has specific residues that are 
key determinants in the mitochondrion-HKI interaction is unclear.  Recombinant wild-type 
HKI binds to mitochondria, but the removal of residues 1-15 abolishes such binding.  
Mutations A4L, A8L and Q5P individually cause a 10-fold decreases (relative to wild-type 
enzyme) in HKI binding to mitochondria.  In contrast, mutations Q5A, Y10L and T12I 
decrease binding by approximately twofold.  The mutations did not affect the catalytic 
properties of the enzyme, and all HKI constructs remained monomeric to concentrations as 
high as 10 micromolar.  Results here are consistent with a helical conformation for the N-
terminus of HKI, with residues A4 and A8 defining a contiguous surface that does not 
tolerate large hydrophobic side chains 
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CHAPTER 1: GENERAL INTRODUCTION 
Hexokinase and its isozymes 
Hexokinases catalyze the phosphorylation of glucose by transferring the γ-phosphoryl group 
from adenosine triphosphate (ATP) to the sixth-position hydroxyl group of glucose to give 
glucose-6-phosphate (Glc-6-P) (1).  There are four isozymes of mammalian hexokinase (HK) 
namely types I, II, III and IV (1,2), which are located in different organs of the body.  Liver 
contains all four types of hexokinases while kidney and intestine contain three (I-III) (2).  
Types I and II are found in epididymal fat pad, skeletal muscle, brain and heart (2).  
However, Type I is predominantly present in brain and kidney and Type II is predominant in 
skeletal muscle and epididymal fat pad (2).  According to Katzen and Schimke, the properties 
of different types of hexokinase do not vary from tissue to tissue but are present in differing 
amounts depending on age, stability, and nutritional factors (2). 
The formation of Glc-6-P by hexokinase commits glucose to alternative metabolic 
pathways: the formation of glycogen and short-term carbohydrate storage in liver; immediate 
use in energy production by glycolysis, and the formation of pentose phosphates for anabolic 
purposes (3) (Figure 1.1).  Different metabolic pathways can be linked to the different organs 
in the body.  These differences may be co-related to the differences between the structure; 
affinity for substrates and inhibitors and subcellular location of the isozymes.  For example, 
HKI and HKII have a tail on the N-terminus that is important in binding of hexokinase to 
mitochondria. Whereas, HKIII and HKIV does not contain the N-terminus and hence is not 
bound to mitochondria. Thus, these isozymes may be associated with metabolic pathways 
other than glycolysis.  
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Fig 1.1 Phosphorylation, catalyzed by hexokinase, is the initial step in common pathways of 
Glc metabolism. (Reference: Wilson, J.E., Isozymes of mammalian hexokinase: structure, 
subcellular localization and metabolic function) 
 
Types I-III have the molecular mass of 100 kDa while type IV, also known as 
glucokinase has a molecular mass of 50 kDa (3-5).  HK types I-III are thought to have 
evolved by the duplication and fusion of an ancestral gene that encodes a 50 kDa hexokinase 
(3 and references therein, 5), the a result of which are N- and C- terminal halves of similar 
sequence (3-5).  Moreover, these terminals have sequence similarity to that of yeast 
hexokinase and glucokinase, which are 50 kDa proteins (3 and references therein,5).  In spite 
of the sequence similarity the N- and C-terminal halves have different function for the 
isozyme Types I-III.  For isozyme II, both halves have catalytic function, whereas for 
isozymes I and III, the C-terminal half has catalytic function and the N-terminal has a 
regulatory function (3, references within, 5). All three isozymes are inhibited by the product 
glucose-6-phospate (Glc-6-P).  It has been hypothesized that inhibition by Glc-6-P is the 
regulatory function of the N-terminal half of HKI and HKIII (3, 5). 
Other differences between the three isozymes are substrate affinity, the role of 
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inorganic phosphate (Pi) in regulation and sub-cellular location.  Of the four isozymes, HKIII 
has the highest affinity for glucose and lowest affinity for ATP.  Glc-6-P inhibits isozyme I-
III, but Pi antagonizes inhibition by Glc-6-P in the Type-I isozyme only and being an 
inhibitor of isozymes II and III.  Isozymes I and II have a conserved hydrophobic leader 
sequence at the N-terminus.  Isozyme III lacks the hydrophobic leader sequence.  
Immunolocalization studies demonstrate we association of isozymes Types-I and -II with 
mitochondria, whereas the Type-III isozyme is co-localized with the envelope of the nucleus 
(3 and references therein, 5).  Hence, the hydrophobic leader sequence for the Types I and II 
isozymes confers mitochondrial binding properties.  Table 1.1 summarizes the similarities 
and differences between the isozymes. 
 
Table 1.1: Summary of the similarities and differences between mammalian isozymes. 
Properties HKI HKII HKIII HKIV 
MW(kDa) 100 100 100 50 
 
Tissues Brain, kidney, 
RBCs 
Skeletal muscle, 
fat 
Liver, intestine, 
kidney 
Liver, pancreas 
Km
Glc 
(mM) 0.03 0.3 0.003 6 
Km
ATP 
(mM) 0.5 0.7 1.0 0.6 
Function, N-
terminal half 
Regulatory Catalytic Regulatory - 
Function, C-
terminal half 
Catalytic Catalytic Catalytic - 
Inhibition by 
Glc-6-P 
Yes Yes Yes No 
Pi relief Yes No No - 
Subcellular 
localization 
Mitochondria Mitochondria Nuclear 
periphery 
- 
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Structure of Hexokinase and G6P Inhibition 
Hexokinase I (HKI) is also called „brain hexokinase‟ (6).  According to Rose and Warms, 
brain hexokinase did not dissociate into subunits under their experimental conditions (7).  
Results obtained by Chou et al. (8) and Easterby (9) established HKI as a single polypeptide 
chain having the molecular weight of 100,000 kDa instead of 50,000 kDa subunits present in 
dimeric yeast hexokinase (8,9).  In a significant extrapolation of these findings, Easterby (9) 
suggested that monomeric HKI evolved from a primordial yeast-like hexokinase through 
gene duplication and fusion (10).  One half of the fused protein retained catalytic function, 
whereas the other half evolved a regulatory function.  White and Wilson, however, suggest an 
alternative evolutionary process in which sensitivity to Glc-6-P had risen prior to gene 
duplication and fusion (12). 
At high enzyme concentrations HKI crystallizes as a dimer (6,11,13-17).  The N- and 
C-terminal halves of HKI have identical folds of the polypeptide chain and are connected by 
an α-helix (11, 14) (Figure1.1).  Moreover, the N- and C-terminal half each has a binding site 
for glucose and Glc-6-P (13).  In the presence of glucose, Glc-6-P occupies an allosteric site.  
In the C-terminal half the allosteric site partially overlaps the putative α-phosphoryl site of 
ATP (14) whereas the Glc-6-P pocket of the N-terminal half overlaps the high-affinity 
binding site for Pi (15). 
The structures of crystallographic dimers are in conflict with result of solution 
studies.  Firstly, HKI is a monomer at low concentrations (<0.5 mg/mL), both in the presence 
and absence of ligands (16,17).  On the basis of equilibrium binding experiments, HKI has 
one high affinity site for G6P (18-20).  In an attempt to nullify the effects subunit 
dimerization Liu et al (21) engineered HKI to be monomeric even at high enzyme 
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concentrations.  Aleshin et al (11,14) crystallized the engineered monomer as a glucose/Glc-
6-P complex and as a glucose/ADP complex and found two binding sites for Glc-6-P and two 
binding sites for ADP (Fig. 1.3).  In parallel with this work Liu et al (21) demonstrated two 
mechanisms of Glc-6-P inhibition, one due to the binding of Glc-6-P to the N-terminal half, 
and the other due to its binding to the C-terminal half.  To this day, however, the mechanism 
of Glc-6-P inhibition remains unclear.  The existence of two mechanisms may be a 
consequence of two radically different environments for HKI in tissues.  In the red blood cell, 
HKI is in the cytosol (not membrane associated), whereas in nerve tissue HKI is associated 
with the mitochondrion.  Glc-6-P inhibition in the red blood cell may come through its 
interaction with the N-terminal domain, whereas Glc-6-P inhibition of HKI in nerve tissue 
may come through its interaction with the C-terminal domain. 
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Fig. 1.1.   Hexokinase x-ray structure (PDB 1HKB).  A. HKI dimer.  B. HKI monomer. C-
terminal half (red), N-terminal half (blue), and α-helical polylinker (yellow). 
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Fig. 1.2.  Ligand binding to HKI (PDB 1HKC).  A. HKI complexed with Glc (blue) and Glc-
6-P (red) in a closed C-terminal conformation.  B. HKI complexed with Pi (red spheres) and 
Glc (blue) in an open C-terminal conformation.  
 
Closed C-terminal  Open C-terminal  
B A 
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Fig. 1.3. Nucleotide binding to HKI (PDB 1CZA). HKI complexed with ADP 
(magenta). 
 
Mitochondrial binding of hexokinase 
Hexokinase I binds to the outer mitochondrial membrane (7, 22, 23) through an 11-residue 
hydrophobic tail on its N-terminus (24).  Xie and Wilson (24) proposed that the hydrophobic 
tail is helical and Mulichak et al. (13) proved it through their crystal structures.  This helical 
tail binds to a porin in the outer mitochondrial membrane (25-27).  Mitochondrial porin (also 
known as the voltage dependent anion channel or VDAC) has a β-barrel structure (28-31).  
VDAC is a 30 kDa protein that allows the voltage-dependent passage of selective anions 
through the outer membrane of the mitochondrion (34).  There are three kinds of VDACs in 
humans, namely VDAC1, VDAC2 and VDAC3 (34).  Human VDAC1 is most abundant and 
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is made of 19 β-strands with an α-helix located horizontally midway within the pore (Fig. 
1.4).  The α-helix is the presumed gate that controls the passage of anions (34). 
 
 
Fig 1.4.  Structure of mouse VDAC1 (PDB 2JK4). A. Side view B. Top view. 
Hexokinase binds to mitochondria for perhaps two reasons: Hexokinase uses ATP as a 
substrate. The colocalization of hexokinase and VDAC gives hexokinase preferential access 
to intra-mitochondrial ATP (7).  Experiments conducted in several laboratories support this 
hypothesis (5, 35-37). Growing tumor cells need large amount of energy produced through 
glycolysis. The amount of hexokinase was found to be greater in tumor cells as compared to 
normal cells (7). Hence, the discovery that hexokinase uses intramitochondrial ATP to initiate 
the glycolysis process was of great importance to understand the uncontrolled growth of 
cancer cells.  
 Nonetheless, when HKI binds to VDAC in patch-clamp experiments, anion 
conductance is terminated (38,39).  By binding to VDAC, HKI blocks the pore.  So how then 
does ATP reach the active site of HKI is unknown. Hence, we cannot say with absolute 
B A 
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certainty that hexokinase uses intramitochondrial ATP to initiate glycolysis.  
Hexokinase also plays an important role in preventing apoptosis.  Hexokinase is 
considered to be the “guardian of the mitochondria” (40) because it binds to VDAC on the 
outer mitochondrial membrane and prevents the release of apoptogenic factors (41).  
Mitochondria house an important co-factor for apoptosis, cytochrome c, which activates 
caspases for apoptosis (40).  In order to release cytochrome c, the permeability transition 
pore (PTP) needs to be opened (41).  PTP is formed by VDAC on the outer mitochondrial 
membrane, adenylate translocator (ANT) on the inner mitochondrial membrane and 
cyclophilin D and other proteins in the matrix (42).  The opening of PTP results in loss of 
membrane potential, swelling of mitochondria, acidification of the cytosol and release of 
cytochrome c (42).  Released cytochrome c thus activates Apaf 1 which initiates caspase 
activation and ultimately results in apoptosis (40). 
Pro-apoptotic factors like Bax and Bak bind to VDAC and thus induce the release of 
cytochrome c from mitochondria (43-44).  Binding of hexokinase to VDAC protects the 
mitochondrion against proteolytic degradation (45).  It might also prevent the binding of Bax 
and Bak to VDAC.  This in turn might prevent the opening of the PTP and release of 
cytochrome c.  Hence, if hexokinase binding to VDAC is lessened or eliminated, 
mitochondrion-based apoptosis can be induced in cells. 
Hypothesis 
Tumor cells metabolize glucose at high rates due to presence of large amounts of hexokinase 
(45).  Hexokinase acts as the guardian of the mitochondria (40) by binding to VDAC through 
its N-terminal residues (24).  Chymostrypsin removes the hydrophobic tail on the N-
terminus, and such proteolyzed hexokinase does not bind to mitochondria (7,32-33).  Hence, 
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the first dozen residues are important in the binding of hexokinase to mitochondria.  In our 
research, we hypothesized that, residues Alanine (4), Alanine (8) and Threonine (12), which 
fall on the same side of the N-terminal helix, interact with VDAC when hexokinase is bound 
to mitochondria.  Hence, we conducted mitochondrial binding experiments using wild-type 
HKI and mutants A4L, A8L and T12I to an effect on the binding of HKI to mitochondria.  
Our findings indicate that positions 4 and 8 cannot have large hydrophobic side chains, most 
likely because this surface of the N-terminal helix binds to VDAC. 
Thesis Organization 
This thesis is organized into three chapters. Chapter 1 covers the general information and 
background about the enzymes hexokinase and voltage dependent anion channel (VDAC); 
their interaction with each other in the outer mitochondrial membrane and their structures. 
Problems and objectives of the thesis research are provided as well.  Chapters 2 is a paper 
prepared for submission for publication in peer reviewed journals.  Chapter 2 shows that the 
N-terminal hydrophobic tail has specific and essential amino-acid determinants that stabilize 
the binding of HKI to the mitochondrion.  Conclusions and recommendations for future 
studies are in Chapter 3. 
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CHAPTER 2: SINGLE-RESIDUE DETERMINANTS IN THE BINDING 
OF RECOMBINANT HUMAN BRAIN HEXOKINASE TO THE 
MITOCHONDRION
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Abstract 
The N-terminal segment (residues 1-15) of hexokinase I (HKI) is essential for the 
binding of HKI to the outer membrane of the mitochondrion.  Whether the N-terminal 
segment is merely a hydrophobic anchor to the membrane or has specific residues that are 
key determinants in the mitochondrion-HKI interaction is unclear.  Recombinant wild-type 
HKI binds to mitochondria, but the removal of residues 1-15 abolishes such binding.  
Mutations A4L, A8L and Q5P individually cause a 10-fold decreases (relative to wild-type 
enzyme) in HKI binding to mitochondria.  In contrast, mutations Q5A, Y10L and T12I 
decrease binding by approximately twofold.  The mutations did not affect the catalytic 
properties of the enzyme, and all HKI constructs remained monomeric to concentrations as 
high as 10 micromolar.  Results here are consistent with a helical conformation for the N-
terminus of HKI, with residues A4 and A8 defining a contiguous surface that does not 
tolerate large hydrophobic side chains. 
                                                 
1
This research was supported in part by National Institute of Health Research Grant 
NS 10546 
3
To whom correspondence should be addressed. 
19 
 
Introduction 
Hexokinases catalyze glucose phosphorylation by adenosine tri-phosphate (ATP) to 
produce glucose 6-phosphate (Glc-6-P).  Mammals have four isozymes of hexokinase: I, II, 
III and IV (1).  Hexokinase I (HKI) or brain hexokinase regulates glucose metabolism in 
brain tissue and the red blood cell (2).  Hexokinases (I-III) have molecular masses of 
approximately 100 kDa (1), consisting of C- and N-terminal halves with significant levels of 
sequence identity to each other and to yeast hexokinase (3).  Hexokinase IV (glucokinase) is 
a 50 kDa protein with a sequence similar to both C-terminal and N-terminal halves of 
hexokinase I-III and to yeast hexokinase (4).  Similarities between mammalian isoenzymes 
evidently originate from the duplication and fusion of a primordial hexokinase gene similar 
to that of yeast hexokinase (5).  A number of ligands inhibit HKI; however, Glc-6-P is 
probably the primary physiological inhibitor of the type-I enzyme (6).  Glc-6-P inhibits HKI 
catalysis by binding with high affinity to either the C- or N-terminal halves (7,8). Under 
normal physiological conditions, inorganic orthophosphate (Pi) decreases Glc-6-P inhibition 
(9).  Pi binds tightly to the N-terminal half of HKI and relieves Glc-6-P inhibition by an 
allosteric mechanism that couples both halves of the enzyme (10) (11).  At elevated levels, Pi 
inhibits HKI by binding to the active site (12). 
 Despite structural similarities, hexokinases (I-III) are functionally different. Both 
halves of HKII support catalysis and are each sensitive to inhibition by Glc-6-P (13), whereas 
only the C-terminal half of HKI and HKIII supports activity (14,15). Nonetheless, Pi can 
relieve Glc-6-P inhibition of HKI alone (4,7-8,12). 
20 
 
 HKI co-localizes on the outer mitochondrial membrane (OMM) in brain tissue 
preferentially close to newly formed ATP inside the mitochondrion (16,17).  In tumor cells, 
mitochondrion-associated HKII antagonizes Bax-induced cytochrome c release and in turn 
inhibits apoptosis (18-20).  Bax interacts with permeability transition pore (PTP) resulting in 
loss of membrane potential, triggering of mitochondrial membrane permeabilization (MPP) 
and release of cytochrome c (21).  Pro-apoptotic proteins such as Bax, Bak, and Bim interact 
with voltage-dependent anion channel (VDAC) forming an assembly of large channels likely 
used for cytochrome c passage from mitochondrion matrix to cytoplasm (22-24).  VDAC is 
part of PTP, which in addition to VDAC, includes the adenylate translocator (ANT) of the 
inner mitochondrion membrane (IMM) (25-29), and cyclophilin D of the inner 
mitochondrion matrix (30-32).  Released cytochrome c activates the caspase family of 
proteases in cytoplasm, which in turn triggers apoptosis (32-34).  VDAC-1 overexpression 
causes apoptotic cell death (35,36).  Hexokinase I and II, in association with VDAC, likely 
antagonize the formation of apoptotic channels.  Some have gone so far as to label 
hexokinase as “guardian of the mitochondria” (37). 
 Over expression of N-terminally truncated VDAC-1 did not induce cells to release 
cytochrome c, and such cells were resistant to apoptosis (38).  N-terminus peptide and other 
VDAC-1 based peptides bind to immobilized HKI, these peptides prevent HKI-protection of 
cells (39).  Chemical modification of Glu 72 prevents HKI from binding to mitochondria 
(35).  Mutating Glu 72 and other residues abolishes HKI-protection against apoptosis in 
cancer cells (40).  Adding HKI to VDAC-1 reconstituted in lipid membrane reduced the 
channel conductance (25); however, the addition of HKI to mutant mouse VDAC-1 E72Q 
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reconstituted in lipid membrane did not block conductance in patch clamp experiments, 
indicating failure of HKI to bind to mutant VDAC-1 (40). 
 A number of small and physiological important ligands are capable of dissociating 
HKI from the mitochondrial outer membrane.  These compounds include Glc-6-P and ATP 
(16).  Skaff et al. (41) demonstrated wild-type recombinant HKI with properties comparable 
to native brain hexokinase including those of mitochondrial-binding and release.  The 
recombinant construct has an intact membrane targeting element and a formyl group attached 
to the amino terminus of the polypeptide chain.  The release properties of mutant constructs 
demonstrated the significance of Glc-6-P binding to the N-terminal half of HKI in promoting 
the release of the mitochondrion-associated enzyme.  Nucleotide-induced release, on the 
other hand, follows a competitive binding model between HKI and nucleotides at a binding 
site on VDAC1 (unpublished data). 
Early studies showed that digesting hexokinase I with proteases resulted in loss of 
mitochondrial binding properties (16).  Rapid purification of rat brain hexokinase using 
HPLC decreased the portion of HKI devoid of mitochondria-binding properties (42,43).  Rat-
brain hexokinase with mitochondrion-binding properties intact is more hydrophobic than the 
non-bindable form (44).  The two enzyme forms (with and without mitochondrial binding 
properties) have similar molecular weights and kinetic properties (45).  N-terminal sequence 
of rat brain hexokinase was determined as a critical determinant of mitochondrial binding of 
HKI (46).  The N-terminus of HKI from native tissue is putatively blocked by an acetyl 
group (47).  Xie and Wilson (1988) proposed a helical conformation of the first 11 residues 
of HKI N-terminus.  This conformation allows the insertion of the N-terminus in a lipid 
bilayer (46,48).  The effect of monoclonal antibodies against rat brain hexokinase varied 
22 
 
from blocking mitochondrial binding to inhibiting Glc-6-P release (49).  Mitochondrial-
bound rat brain hexokinase was released upon exposure to monoclonal antibodies raised 
against the N-terminus (50). 
Although some studies stress that hexokinase binding to mitochondria is determined 
by the hydrophobicity of the tail (51,52), HKI cellular co-localization with VDAC on OMM 
(17) implies more complex and specific interactions than general hydrophobic interactions 
with lipid.  To date, no single residue has been proven essential to hexokinase association 
with the mitochondrion.  Yet inspection of the putative N-terminal helix of HKI reveals 
amino acids with small side chains localize to only one face of the helix, whereas large side 
chains occupy all other faces.  Does the helix surface defined by small side chains make 
critical contacts with a protein binding partner (presumably VDAC) in the outer  membrane 
of the mitochondria?  Indeed, the mutation of Ala 4 and Ala 8 to leucine abolished 
hexokinase association with the mitochondrion, whereas mutations at other residues have 
little or no effect.  The discovery of a localized surface critical to hexokinase association with 
the mitochondrion provides a useful constraint in modeling possible HKI-VDAC complexes. 
Experimental Procedures 
Materials—ATP, Glc-6-P, ampicillin, deoxyribonuclease (DNase I), bovine serum albumin 
(BSA), leupeptin, protease cocktail inhibitor and phenylmethylsulfonyl fluoride (PMSF) 
came from Sigma.  DEAE HPLC resin was a product of Tosohaas. E.coli strain BL21 (DE3) 
competent cells were from Novagen.  Glucose-6-phosphate dehydrogenase was obtained 
from Roche Molecular Biochemicals.  Isopropyl-1-thio-β-D-galactopyranoside (IPTG) came 
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from Anatrace. Sequencing PVDF membranes (ProSorb sample preparation cartridge) were 
purchased from Applied Biosystems. 
Construction of Wild-type Hexokinase and Mutant Plasmids—Human brain hexokinase 
(HKI) had been cloned into pET-11a as reported in a previous study (41).  Hexokinase 
mutants were created through PCR modification with oligonucleotide primers synthesized at 
the Iowa State University DNA Sequencing and Synthesis Facility.  Mutants Ala4Leu, 
Ala8Leu, Thr12Ile, Gln5Ala and Gln5Pro were created with the following forward primers 
(and their reverse compliments) respectively: 
5'CATATGATCGCCCTGCAGCTCCTGGCC-3'; 
5'CGCAGCTCCTGCTCTATTACTTCACGGAGC-3'; 
5'GCCTATTACTTCATTGAGCTGAAGGATG-3'; 
5'GATCGCCGCGGCGCTCCTGGCC-3'; 
5'GATCGCCGCGCCGCTCCTGGCC-3'. 
Iowa State University DNA Sequencing and Synthesis Facility confirmed all final constructs 
by sequencing the DNA of the entire gene. Mutant Y10L was used in previous studies 
(unpublished data). 
Expression and Purification of Wild-Type and Mutant Hexokinases— Wild-type or mutant 
pET-211a-HKI plasmids were transformed into E.coli strain BL21 (DE3).  Expression and 
purification of HKI enzymes were previously discussed (41).  Protein concentrations 
employed the Bradford method with bovine serum albumin as a standard (53). 
Pig Liver Mitochondria Purification— Pig livers were obtained from the Iowa State 
University Meats Laboratory shortly after slaughter.  Mitochondrial purification is described 
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(54) with modifications as discussed elsewhere (41).  Both outer mitochondrial membrane 
(OMM) and inner mitochondrial membrane (IMM) integrities were measured as described 
previously (55, 56).  Mitochondria were stored at –80º C in the presence of 5% dimethyl 
sulfoxide. 
The HKI Activity Assay— Hexokinase activity was measured using the glucose 6-phosphate 
dehydrogenase (G6PDH)-coupled spectrophotometric assay.  Assay solutions have 3mM 
MgCl2, 3 mM DTT, 0.3 mM NADP and 10 g/mL G6PDH in 50 mM Tris-HCl, pH 8.0, and 
concentrations of glucose and ATP:Mg
2+
 that varied from 1/5 x Km to 5 x Km.  NADPH 
production was monitored at 340 nm wavelength.  Reaction was initiated by the addition of 
enzyme and linear progress curves monitored for 3 minutes.  Slopes were used to calculate 
initial rates in umole/min.  The capacity of the coupling enzymes was verified by observing a 
twofold increase in velocity with a doubling of added hexokinase.  Initial rate data were 
analyzed using GraFit (57). 
Mitochondrial Binding and Release— Purified HKI was dialyzed twice against 
mitochondrial-binding buffer (250 mM sucrose, 5 mM Glc, 50 mM NaCl, 5 mM MgCl2 and 
50 mM HEPES, pH 7.4), and then diluted to 2 mg/mL using the same buffer.  Thirty mg wet 
weight of mitochondrion, thawed on ice, was suspended in 1 mL of mitochondrial-binding 
buffer, and then collected by centrifugation at 11,000 × g for 5 minutes.  Suspension and 
centrifugation steps were repeated twice.  The pellet was suspended in 1 mL of 
mitochondrial-binding buffer with added HKI (2 mg/mL), protease cocktail inhibitor (0.25 
mg/mL) and PMSF (1 mM).  After 60 minutes on ice, the mixture of HKI and mitochondria 
was centrifuged at 11,000 × g for 5 minutes.  Unbound HKI in the supernatant fluid was 
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decanted.  Pelleted mitochondria were suspended in mitochondrial-binding buffer, less the 
MgCl2, NaCl, and glucose, and centrifuged again.  This wash step was twice-repeated. 
HKI-bound mitochondria, prepared as above, is suspended in release buffer (250 mM 
sucrose and 50 mM HEPES, pH 7.4).  50 μL aliquots of this suspension were distributed to 
plastic micro-centrifuge tubes, to which were added a release agent (ATP, TNP-nucleotide, or 
Glc-6-P) at various concentrations.  After 30 minutes at room temperature, the mitochondria 
were pelleted by centrifugation.  HKI solubilized by nucleotide was removed by decanting 
the supernatant liquid.  The mitochondrial pellet was suspended in wash buffer (250 mM 
sucrose and 5 mM HEPES, pH 7.4), and centrifuged.  After discarding the supernatant fluid, 
pelleted mitochondria were suspended in 100 L wash buffer and then assayed for 
hexokinase activity. 
Results 
Mitochondria integrity— The outer membrane integrity of the mitochondrion preparation 
was 90% as indicated by the cytochrome c oxidase activity assay (data not shown).  Inner 
membrane integrity was confirmed by mitochondrial uptake of the cationic carbocyanine dye 
JC-1 (data not shown). 
Rationale for the selection of HKI mutants—Xie and Wilson (46) predicted a helical structure 
for the first 11 residue sequence of rat brain HKI, which was confirmed subsequently the 
structure of the rat HKI (58) (Fig. 2.1).  This sequence is identical to that of human brain HKI 
(Fig. 2.1).  The helical conformation for these initial residues puts Ala 4, Ala 8 and Thr 12 on 
the same face of the helix (Fig. 2.1).  Other faces of the helix have predominantly residues 
with large hydrophobic side chains.  The alignment of small residues on one face of the N- 
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Fig. 2.1 Structure of HKI.  A. Ribbon of HKI.  The image shows the N-terminal α-
helix with positions 4, 8, and 12 in dark gray.  B. Stick model of the N-terminal helix 
(light gray).  Residues targeted for mutation (dark gray) lie on one side of the helix.  
Model adapted from crystal structure of HKI (PDB ID 1CZA).  C. Human brain 
hexokinase (NCBI Reference Sequence: NP_000179.2) and rat brain hexokinase 
(GenBank: AAC20075.1) aligned by LALIGN (59). 
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terminal helix could facilitate packing of the helix against a relatively uniform surface of on 
the β-barrel of VDAC1.  If so, then mutations of position 4, 8, and 12 to larger hydrophobic 
residues should decrease the binding of HKI to mitochondria.  The mutation of position 5 to 
proline should destabilize the helix and thereby disrupt mitochondrial association. 
Size exclusion— Size exclusion chromatography of wild-type HKI and mutants revealed a 
major band corresponding to a protein of mass 100 kDa (Table 2.1 and Fig. 2.2). 
 
 
 
Table 2.1.  Molecular weights of wild-type and mutant hexokinases as determined 
by size exclusion chomatography. 
 
 HKI construct 
 WT Y10L A4L A8L T12I Q5A Q5P 
MW (kDa) 105 (7) 96 (4) 100 (6) 99 (9) 115 (10) 103 (6) 95 (5) 
Linear regression equation of calibration curve (Figure 2.2) was used to calculate 
apparent molecular weights of wild type and mutant HKI. 
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A       B 
C 
 
Fig. 2.2.  Size exclusion chromatography of HKI constructs.  A. Elution profiles of 
standard proteins.  B. Calibration curve of log molecular weights of standard proteins 
versus retention times.  C. Elution profiles of wild-type and mutant HKI.  The 
concentration of wild-type and mutant HKI was 1 mg/mL.  A sample of volume 100 
µL was injected onto a TSK-G3000SW type size-exclusion column and eluted with 5 
mM glucose, 1 mM DTT, and 25 mM KPi, pH 7.4.  Absorbance was monitored at 
280 nm. 
29 
 
HKI and mutants properties— Purified proteins here were at least 95% pure on the basis of 
sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE).  Each hexokinase 
was prepared twice, and used immediately upon purification in mitochondrial binding, gel-
filtration and kinetics experiments.  Mutant hexokinases have kcat, Km
Glc
 and Km
ATP
 
comparable to those of wild-type HKI (Table 2.2).  Edman degradation of wild-type and 
mutant hexokinases (400 picomole of purified enzyme) either provided no sequence 
information or weak signals for sequences beginning at residues 10 and 12.  The vast 
majority of enzyme molecules in each sample had blocked N-terminal residues that resisted 
Edman degradation.  Efforts to deformylate the N-terminus by incubation with 0.6 M HCl 
failed. 
Table 2.2.  Kinetic properties of HKI constructs. 
HKI construct kcat (s
-1
) Km
ATP
 (mM) Km
Glc
 (µM) 
Wild-type 92 (11) 0.58 (6) 40 (5) 
Y10L 95 (15) 0.54 (4) 19 (3) 
A4L 93 (7) 0.99 (8) 24 (3) 
A8L 103 (15) 0.87 (7) 24 (5) 
T12I 89 (9) 0.57 (5) 23 (4) 
Q5A 98 (10) 0.60 (4) 20 (4) 
Q5P 77 (4) 0.82 (2) 24 (6) 
Determination of kcat employed concentrations of Glc and ATP of 1.6 mM and 9 mM 
respectively.  Determination of Km
ATP
 employed at Glc concentration of 1.6 mM and 
concentrations of ATP of 0.3–7.5 mM.  Determination of Km
Glc
 employed an ATP 
concentration of 9 mM and concentrations of Glc of 10–600 μM. 
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Wild-type and mutant hexokinase I binding to mitochondria— Scheme I represents the 
simplest equilibrium model that accounts for the binding of wild-type and mutant 
hexokinases to the mitochondria: 
 
K1 = [EQ]/[E][Q] 
      Scheme I 
In Scheme I, K1 represents an association constant for the binding of the HKI construct 
(represented by E) to specific mitochondrial binding sites Q.  As demonstrated by previous 
work, nonspecific binding to the mitochondrion by HKI does not occur at significant levels.  
The ratio of enzyme bound to total Eo is as follows: 
R([E]) = (K1[E])/(1+K1[E])       Eq. 1 
The concentration of free specific mitochondrial sites Q is itself a function of the 
concentration of enzyme.  Algebraic manipulation of the equilibrium expression in Scheme I 
and relationships for mass conservation of total enzyme Eo and total specific sites Qo results 
in a quadratic relationship in E: 
a[E]
2
 + b[E] + c = 0 
where a = K1, b = K1(Qo–Eo)+1, and c = –Eo.  The physical root of the quadratic equation 
gives [E]: 
[E] = –{K1(Qo–Eo)+1}/2K1 + {K1
2
(Eo–Qo)
2
+2K1(Eo+Qo)+1}
1/2
/2K1  Eq. 2 
Substitution of Eq. 2 into Eq. 1provides a relationship for the fraction of enzyme bound to the 
mitochondria as a function of Eo, Qo and K1. 
The fitting relationship is V = sR(Eo,Qo,K1) (Eq. 3), where s is a proportionality 
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constant that relates the fraction of bound enzyme R to velocity V in μmoles/min.  Undefined 
quantities s, Eo, Qo, and K1 cannot be determined by a nonlinear least squares fit of the data 
from a single experiment.  Hence, values for some of these quantities must come from other 
determinations.  Firstly, one assumes the HKI-VDAC complex has an equal number of HKI 
and VDAC subunits.  The value for Qo (7.1x10
–8
 M) then is an estimate based on 42,000 
VDAC molecules per mitochondrion (60), 7.2x10
9
 mitochondria per 1 mg of total 
mitochondrial protein (61), and 0.014 mg of mitochondria in each 100 µL assay.  Moreover, s 
= Qo×(specific activity)×(assay volume), where the specific activity for HKI is 6x10
9
 
μmole/min-1 mole-1 and the assay volume is liters.  Hence, if the assumption of a 1:1 ratio of 
the HKI-VDAC complex is correct, then data can be fit to Eq. 3 using K1 alone as an 
adjustable parameter.  Data fit by this method appears in Fig. 2.3.  Listed in Table 2.3 are 
values for K1 for wild-type and mutant constructs of HKI. 
Glc-6-P induced release of Wild-type and mutant hexokinase I from mitochondria— Glc-6-P 
releases wild-type HKI from mitochondria as well as T12I, Y10L and Q5A (Table 2.4).  The 
model and fitting is as described previously (41). Release experiments could not be done for 
the A4L, A8L, and Q5P constructs due to poor binding to the mitochondrion. 
ATP-induced release of Wild-type and mutant hexokinase I from mitochondria— ATP 
released wild-type, T12I, Y10L and Q5A hexokinases from the mitochondrion (Table 2.5 and 
Fig. 2.4.).  The model and fitting is as described by Nimer (PhD thesis).  Release experiments 
could not be done for the A4L, A8L, and Q5P constructs due to poor binding to the 
mitochondrion. 
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 Fig. 2.3. HKI binding to pig liver mitochondria. Plots represent velocities 
from varying concentrations of wild-type (○), T12I (▲), Y10L (■), Q5A (●), Q5P 
(□), A4L () or A8L () bound to 1.8 mg, wet weight  mitochondria (each fraction) in 
250 mM sucrose and 50 mM HEPES, pH 7.5. The solid lines represent fitted curves 
using Eq. 3 with parameters given in the Results section and Table 2.3. 
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Table 2.3.  Fitted parameters for wild type and mutant HKI binding to pig liver 
mitochondria. 
HKI 
construct 
Apparent association  
constant K1 (M
-1
) 
WT 2.7 x 10
4
 (6.5 x 10
2
) 
Y10L 1.4 x 10
4
 (7.3 x 10
2
) 
A4L 3.6 x 10
3
 (1.6 x 10
2
) 
A8L 3.5 x 10
3
 (1.5 x 10
2
) 
T12I 2.0 x 10
4
 (7.0 x 10
2
) 
Q5A 8.9 x 10
3
 (4.3 x 10
2
) 
Q5P 4.5 x 10
3
 (1.5 x 10
2
) 
Parameter K1 is defined in the Result section. HKI bound to 1.8 mg, wet weight 
mitochondria (each fraction) in 250 mM sucrose and 50 mM HEPES, pH 7.5 was 
measured by activity. Standard deviations in the last significant digits are given in 
parenthesis. 
 
 
  
Table 2.4. Fitted parameters for Glc-6-P-induced release of mitochondrial wild type and mutant HKI. 
HKI construct a 
(µMS
-1
) 
b 
 
c 
(µM
-1
) 
Kii 
(mM) 
I0.5 
(µM) 
Relative 
velocity at I0.5 
Limiting 
release 
% 
WT 0.035 (7) 6 (2) 1.1 (4) 0.2 (1) 3.0 (1) 0.70 (5) 47 (3) 
T12I 0.040 (6) 5 (2) 1.1 (3) 0.3 (1) 2.7 (3) 0.67 (6) 48 (3) 
Y10L 0.028 (4) 4 (2) 0.9 (2) 0.4 (2) 2.8 (4) 0.63 (5) 54 (6) 
Q5A 0.047 (1) 8 (1) 1.5 (1) 0.3 (1) 3.4 (4) 0.74 (2) 40 (2) 
Parameters a, b, c, Kii, and I0.5 previously described (41). Mitochondria with HKI bound in 250 mM sucrose and 50 mM 
HEPES, pH 7.5, were exposed to varying Glc-6-P concentrations for 30 minutes. Remaining mitochondria bound HKI was 
measured by activity. Standard deviations in the last significant digit are given in parentheses.
3
4
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Table 2.5.  ATP-dependent release of HKI from pig liver mitochondria. 
FHKI construct K1
 
 (M
-1
) K3  (M
-1
) 
WT 2.5 x 10
6
 (7.3 x 10
4
) 3.0 x 10
3
 (4.1 x 10
2
) 
T12I 1.7 x 10
6
 (6.3 x 10
4
) 8.0 x 10
3
 (1.2 x 10
2
) 
Y10L 4.9 x 10
6
 (1.9 x 10
5
) 3.0 x 10
3
 (5.0 x 10
2
) 
Q5A 2.4 x 10
6
 (1.0 x 10
5
) 1.0 x 10
4
 (1.7 x 10
3
) 
Parameters are from an equilibrium model in which the binding of nucleotide and HKI to 
the mitochondrion is mutually exclusive.  K1 and K3 are constants for the dissociation in 
M
-1
 of HKI and ATP from the mitochondrion. Mitochondria with HKI bound in 250mM 
sucrose and 50 mM HEPES, pH7.5, were exposed to varying concentrations of ATP for 
30 minutes. Remaining mitochondria bound HKI was measured by activity. Standard 
deviations in the last significant digits are given in parentheses. 
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 Fig. 2.5.  ATP-induced release of wild-type and mutant HKI from pig liver 
mitochondria.  Mitochondria with bound wild type (), T12I (○), Y10L (●) or Q5A (▲) 
in 250mM sucrose and 50 mM HEPES, pH7.5, were exposed to varying concentrations 
of ATP . Plots represent relative velocities from mitochondria-bound bound HKI that 
remains after exposure to varying concentrations of ATP. The solid lines represent fitted 
curves using fitting model described by Nimer et al. (unpublished data).  
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Discussion 
K1 of Scheme I represents binding affinity of HKI for the mitochondrion, but binding 
sites on the mitochondrion may be heterogeneous.  VDAC molecules may exist as monomers, 
dimers, or in assemblies of large number.  Nonetheless each class obeys the relationships of 
Scheme I, provided that HKI binds without cooperativity to large aggregates of VDAC.  For a 
dispersive system, K1 becomes a weighted average of association constants for each class of 
binding site: 
  K1 = (∑
i
K1[Qi])/∑[Qi] 
where the summations extend over i classes of binding sites with association constants 
i
K1 and 
[Qi] is the concentration of mitochondrial binding sites in each class.  The effect of site 
heterogeneity is a K1 that depends on the concentrations of total enzyme Eo and mitochondrial 
sites Qo.  For instance, high ratios of Eo to Qo will result in low values for K1, as subclasses of 
binding sites with low association constants contribute to the ensemble average. Wilson et al. 
(46) have published the only binding curve for which the number of mitochondrial binding sites 
Qo is in great excess over Eo.  Applying the model used here to these data yields a K1 of 1.4x10
6
 
M
-1
.  The number determined from (46) agrees well with the K1 of nucleotide release assays 
(Table 2.5), but is 100-fold higher than the K1 determined from binding assays (Table 2.3).  The 
discrepancy lies in the relative abundance of HKI and mitochondria for the release and binding 
assays.  Specifically for all data points in release assays [HKI] ≤ Qo, whereas for binding assays 
[HKI] ≥ Qo.  The consequence of different experimental conditions is a K1 that differs by 100-
fold. 
Pittler et. al. (47) proposed that an N-acetyl group blocks the N-terminus of native rat-
brain hexokinase.  In the present study, the N-termini of wild-type and mutant hexokinases resist 
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Edman degradation.  Deformylation of C-terminal His-tagged human HKI removed the blocking 
group, resulting in a clear hexokinase sequence beginning with the N-terminal methionine (41).  
The same procedure, however, did not deblock recombinant HKI, used here, which is expressed 
from a vector which does not incorporate a C-terminal His-tag.  There are now many reports of 
recombinant proteins expressed in E. coli with an N-acteyl group at the N-teminus (62).  The 
status of the N-terminus of HKI constructs is critical, because the loss of either the blocking 
group or N-terminal residues could greatly alter the binding affinity toward the mitochondrion.  
Each of the constructs here has a blocked N-terminus, and hence, changes in binding properties 
relative to the wild-type enzyme must be a consequence of a specific mutation. 
Several mechanisms could be responsible for the disruption of HKI binding affinity to the 
mitochondrion.  Mutations could cause global conformational change in the protein; however, 
kinetic parameters clearly indicate active enzyme with wild-type properties.  Moreover, the 
removal of residues from the N-terminus has no effect on the kinetic properties of HKI (or 
hexokinase Type-II) from human and other sources (63,64).  Mutations could also change the 
state of aggregation of HKI, and thereby impede association with the mitochondrion, but 
constructs here are monomers up to peak concentrations used in mitochondrial binding assays.  
Hence, decreased binding affinities observed here are due the effect of the mutation on the 
specific interactions with the mitochondrion. 
Although HKI binds to hydrophobic surfaces (48), specific binding of HKI to 
mitochondria cannot be explained merely by hydrophobic interactions with a lipid bilayer (46).  
Mutations at positions 4 and 8 identify the first single-residue determinants essential for the 
interaction of HKI with the mitochondrion.  The loss of binding properties due to the Gln5→Pro 
mutation infers a helical conformation for the N-terminal residues of mitochondrion-bound HKI.  
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Hence, positions 4 and 8 define a contiguous surface that does not allow large residues, even if 
these residues are hydrophobic.  Other positions seem less important, and allow conservative 
changes in the type of amino acid side chain, but no mutation improved mitochondrial binding. 
Cyclic AMP-dependent protein kinase, D-AKP1, binding to mitochondria and 
endoplasmic reticulum is also controlled by a 15-residue N-terminal sequence homologous to 
that of HKI (52).  Small hydrophobic side chains on residues corresponding to residues Ala
4
 and 
Ala
8
 in HKI tail are necessary for mitochondrial targeting (52).  Moreover, the amount of HKI 
that binds to the mitochondrion diminishes as residues are removed from the N-terminal 
sequence (51).  Thr
12
 is on the same helical face as Ala
4
 and Ala
8
, but the mutation of position 12 
to isoleucine has less impact on mitochondrial binding properties of HKI; however, the steric 
bulk at position 12 increases by only single methyl group, whereas positions 4 and 8 have 
additions of isopropyl groups.  Ala4 and Ala8 are not likely critical for lipid interactions, but 
would define a relatively flat surface on the N-terminal helix.  Such a surface would pack 
favorably against a flat exterior surface of the β-barrel of VDAC.  Preliminary coarse grain 
modeling (Yang Gao and Richard Honzatko, unpublished results) indicates a preferred placement 
of the surface defined by positions 4 and 8 on the barrel of VDAC.  This placement puts the N-
terminal domain of HKI over the opening of the anion pore of VDAC, consistent with the 
channel-blocking properties of HKI. 
Although N-terminal residues are essential for HKI association with the mitochondria, 
one cannot exclude the possibility of other residues elsewhere on HKI playing an essential role 
(65).  Nucleotide (Nimer et al.) and Glc-6-P (41) release of mitochondrion-bound HKI implicate 
the pore of VDAC and the Glc-6-P binding pocket of the N-terminal half of HKI in the VDAC-
HKI recognition.  If VDAC favors an open conformation for the N-terminal half of HKI, then 
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Glc-6-P could disrupt essential contacts by driving the N-terminal domain to its closed 
conformation.  The binding of nucleotides to VDAC could alter the conformation of the pore, 
disrupting the same VDAC-HKI interactions.  Finally, the N-terminal hydrophobic helix of HKI 
continues beyond residue 15 and becomes highly charged with acid and basic side chains.  Some 
of these charged residues are in position to interact with VDAC.  Given the current work 
establishes a method of quantifying the effects of a mutation on mitochondrion binding affinity, 
one can systematically mutate residues suggested by a HKI-VDAC model to locate additional 
residues on HKI critical to mitochondrion-binding. 
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46 
 
CHAPTER 3: GENERAL CONCLUSIONS 
 
Loss of mitochondrial binding properties due to the loss of the 15 N-terminal residues of 
rat-brain HKI suggests that one or more of these residues are necessary for the binding of HKI to 
the membrane.  No single-residue determinants of HKI mitochondrial-binding are known.  This 
study reports two residues are essential for binding.  Selective mutations amongst the first 15 
residues have no effect on kinetic properties of HKI.  And wild-type and mutant enzymes behave 
identically as monomers in solution.  The N-terminus in all constructs is blocked by an unknown 
functional group that prevents sequencing by Edmund degradation.  Mutant enzymes A4L and 
A8L do not bind to the mitochondrion.  These residues define a contiguous surface of the N-
terminal helix of HKI.  That surface does not tolerate large hydrophobic side chains, indicating a 
close contact between it and a mitochondrial binding partner (VDAC-1). 
It was hypothesized that the Q5P mutation would completely disrupt the helix and thus 
hexokinase would not bind to mitochondria.  However, the results show that mutant hexokinase 
binds very weakly to mitochondria.  These results suggest that other residues might be playing an 
important role in binding of hexokinase to VDAC and stabilizing it. 
Further studies could include the mutation of charged residues 16, 17, 20 and 21, which 
are above the N-terminal tail, and to measure the effects on the binding properties of hexokinase. 
Similar binding studies can be done on a combination of mutations in the first 25 residues. 
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